Novo Nordisk Cuts Guidance as U.S. Challenges Intensify

The drugmaker warned its revenue could fall in 2017, knocking more than 9% off its share price, as the insulin giant grapples with intensifying competition in the crucial U.S. market.

from WSJ.com: US Business http://ift.tt/2km2IzE
via IFTTT